Current Approaches to Low Vision (Re)Habilitation
PDF
Cite
Share
Request
Review
VOLUME: 49 ISSUE: 3
P: 154 - 163
June 2019

Current Approaches to Low Vision (Re)Habilitation

Turk J Ophthalmol 2019;49(3):154-163
1. Private Niv Eye Center, Ophthalmology Clinic, Adana, Turkey
2. Ankara University, Artificial Vision and Low Vision Rehabilitation, Master Student with Thesis in Vision, Ankara, Turkey
3. Ankara University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey
4. Center of Vision Research and Low Vision Rehabilitation, Ankara, Turkey
No information available.
No information available
Received Date: 05.09.2018
Accepted Date: 19.10.2018
Publish Date: 27.06.2019
PDF
Cite
Share
Request

ABSTRACT

With increased life expectancy at birth and especially the rising incidence of age-related macular degeneration, low vision (re)habilitation is becoming more important today. Important factors to consider when presenting rehabilitation and treatment options to patients presenting to low vision centers include the diagnosis of the underlying disease, the patient’s age, their existing visual functions (especially distance and near visual acuity), whether visual loss is central or peripheral, whether their disease is progressive or not, the patient’s education level, and their expectations from us. Low vision patients must be guided to the right centers at the appropriate age, with appropriate indications, and with realistic expectations, and the rehabilitation process must be carried out as a multidisciplinary collaboration.

Keywords:
Low vision, low vision (re)habilitation, Current approaches, LVA

Introduction

Visual impairment in low vision (re)habilitation may be central or peripheral vision loss or reduced vision due to media opacity. Among these groups, the most common diagnosis in patients presenting to low vision clinics is age-related macular degeneration (AMD), which causes central vision loss.1,2,3,4,5,6,7

The type of rehabilitation required by the low vision patient varies depending on their visual acuity, age, sociocultural status, and especially their diagnosis. The approach to a patient who has central scotoma due to AMD is quite different from the approach to a patient who has tunnel vision due to retinitis pigmentosa. Some cases can involve the coexistence of both central and peripheral vision loss, as in the patient with concurrent diabetic maculopathy and diabetic retinopathy who underwent argon laser treatment to the peripheral retina.

The aim of low vision rehabilitation is for patients to use their residual vision as effectively and efficiently as possible to enable them to live as self-sufficient, independent, and productive individuals, to make their lives easier, and enhance their quality of life. Low vision rehabilitation is not limited to simply recommending aids such as telescopic glasses or magnifying glasses. More important are training in the use these devices and the rehabilitation process. Rehabilitation is a collaborative effort involving many professional groups, such as vocational therapists, psychologists, and social workers, led by an ophthalmologist.

The Vision Research and Low Vision Rehabilitation Center of the Department of Ophthalmology of Ankara University Faculty of Medicine is the first vision rehabilitation center in Turkey to be established within the body of a university, and has facilitated the rehabilitation of 5500 individuals with low vision to date. The center also runs a thesis master’s program on the subject for ophthalmologists.

Conclusion

There are many exciting and promising developments regarding the rehabilitation and treatment of patients with low vision. However, a patient’s age, diagnosis, education level, and sociocultural status should be considered when presenting rehabilitation and treatment options, and patients with low vision should be guided at the right age, to the right centers, and most importantly, with realistic expectations.

References

1
Humphry RC, Thompson GM. Low vision aids-evaluation in a general eye department. Trans Ophthalmol Soc UK. 1986;105:296-303.
2
Temel A. Low vision aids (evaluation of 185 patients). Ophthalmic Physiol Opt. 1989;9:327-331.
3
Van Rens GHMB, Chmielowski RJM, Lemmens WAJG. Results obtained with low vision aids. Doc Ophthalmol. 1991;78:205-210.
4
Üretmen Ö, Yağcı A, Eğrilmez S, Kerci G, Ardıç K. Düşük görme yardımcıları ile klinik sonuçlarımız. MN Oft. 1999;6:261-265.
5
Akyurt, Akın. Az görenlere yardım gerekliliği ve etkinliği. Turk J Ophthalmol. 2003;33:154-160.
6
Tatlıpınar S, Kadayıfçılar S, Eldem B. Yaşa bağlı makula dejenerasyonu olgularında az görenlere yardım cihazı uygulamaları ve sonuçları. Turkish Journal Geriatrics. 2001;4:19-21.
7
Altınbay D. Az görenlere yardım cihazı uygulamaları ve teleskopik gözlük kullanma oranları. Turk J Ophthalmol. 2013;43:427-431.
8
Peli E, Bowers AR, Keeney K, Jung JH. High-Power Prismatic Devices for Oblique Peripheral Prisms. Optom Vis Sci. 2016;93:521-533.
9
Apfelbaum H, Peli E. Tunnel Vision Prismatic Field Expansion: Challenges and Requirements. Transl Vis Sci Technol. 2015;4:8.
10
Gall C, Sabel BA. Reading performance after vision rehabilitation of subjects with homonymous visual field defects. PM R. 2012;4:928-935.
11
Rohrschneider K, Bültmann S, Springer C. Use of fundus perimetry (microperimetry) to quantify macular sensitivity. Prog Retin Eye Res. 2008;27:536-548.
12
Kameda T, Tanabe T, Hangai M, Ojima T, Aikawa H, Yoshimura N. Fixation behavior in advanced stage glaucoma assessed by the MicroPerimeter MP-1. Jpn J Ophthalmol. 2009;53:580-587.
13
Şentürk F, Karaçorlu SA, Özdemir H, Karaçorlu M, Uysal Ö. Klasik ve gizli koroid neovaskülarizasyonlarında mikroperimetrik değişiklikler. Ret-Vit. 2007;15:277-281.
14
Ozturk F, Yavas GF, Küsbeci T, Ermis SS. A comparison among Humphrey field analyzer, micro-perimetry and Heidelberg retinal tomograph in the evaluation of macula in primary open-angle glaucoma. J Glaucoma. 2008;17:118-121.
15
Lima VC, Prata TS, De Moraes CG, Kim J, Seiple W, Rosen RB, Liebmann JM, Ritch R. A comparison between microperimetry and standard achromatic of the central visual field in eyes with glaucomatous paracentral visual-field defects. Br J Ophthalmol. 2010;94:64-67.
16
Fujii GY, de Juan E Jr, Humayun MS, Sunness JS, Chang TS, Rossi JV. Characteristics of visual loss by scanning laser ophthalmoscope microperimetry in eyes with subfoveal choroidal neovascularization secondary to age related macular degeneration. Am J Ophthalmol. 2003;136:1067-1078.
17
Vingolo EM, Cavarretta S, Domanico D, Parisi F, Malagola R. Microperimetric biofeedback in AMD patients. Appl Psychophysiol Biofeedback. 2007;32:185-189.
18
Giacomelli G, Virgili G, Giansanti F, Sato G, Cappello E, Cruciani F, Varano M, Menchini U. Clinical and microperimetric predictors of reading speed in low vision patients: a structural equation modeling approach. Invest Ophthalmol Vis Sci. 2013;54:4403-4408.
19
Calabrèse A, Bernard JB, Faure G, Hoffart L, Castet E. Clustering of Eye Fixations: A New Oculomotor Determinant of Reading Speed in Maculopathy. Invest Ophthalmol Vis Sci. 2016;57:3192-3202.
20
Cideciyan AV, Swider M, Aleman TS, Feuer WJ, Schwartz SB, Russell RC, Steinberg JD, Stone EM, Jacobson SG. Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. Invest Ophthalmol Vis Sci. 2012;53:841-852.
21
Schlimgen M, Fortin MJ, Joondeph BC. OCT imaging in eyes with an implanted telescope. Retina Today. 2015;10:51-52.
22
Agarwal A, Lipshitz I, Jacob S, Lamba M, Tiwari R, Kumar DA, Agarwal A. Mirror telescopic intraocular lens for age-related macular degeneration: design and preliminary clinical results of the Lipshitz macular implant. J Cataract Refract Surg. 2008;34:87-94.
23
Potgieter FJ, Claoue CM. Safety and efficacy of an intraocular Fresnel prism intraocular lens in patients with advanced macular disease: initial clinical experience. J Cataract Refract Surg. 2014;40:1085-1091.
24
Hengerer FH, Artal P, Kohnen T, Conrad-Hengerer I. Initial clinical results of a new telescopic IOL implanted in patients with dry age-related macular degeneration. J Refract Surg. 2015;31:158-162.
25
Khoramnia R, von Mohrenfels CW, Salgado JP, Schweiger B, Engel M, Hadeler J, Lohmann CP. The IOL-Vip system: Principles and clinical application. Ophthalmologe. 2010;107:274-280.
26
Scharioth GB. New add-on intraocular lens for patients with age-related macular degeneration. J Cataract Refract Surg. 2015;41:1559-1563.
27
Nekolova J, Rozsival P, Sin M, Jiraskova N. Scharioth Macula Lens: A new intraocular implant for low-vision patients with stabilized maculopathy-first experience. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017;161:206-209.
28
Tremblay EJ, Stamenov I, Beer RD, Arianpour A, Ford JE. Switchable telescopic contact lens. Opt Express. 2013;21:15980-15986.
29
Arianpour A, Schuster GM, Tremblay EJ, Stamenov I, Groisman A, Legerton J, Meyers W, Amigo GA, Ford JE. Wearable telescopic contact lens. Appl Opt. 2015;54:7195-7204.
30
Schuster GM, Arianpour A, Cookson S, Zhang A, Hendrik L, O’Brien T, Alvarez A, Ford JE. Wink-controlled polarization-switched telescopic contact lenses. Appl Opt. 2015;54:9597-9605.
31
Vincent SJ. The use of contact lens telescopic systems in low vision rehabilitation. Cont Lens Anterior Eye. 2017;40:131-142.
32
Yue L, Falabella P, Christopher P, Wuyyuru V, Dorn J, Schor P, Greenberg RJ, Weiland JD, Humayun MS. Ten-year follow-up of a blind patient chronically implanted with epiretinal prosthesis Argus I. Ophthalmology. 2015;122:2545-2552.
33
Ho AC, Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Handa J, Barale PO, Sahel JA, Stanga PE, Hafezi F, Safran AB, Salzmann J, Santos A, Birch D, Spencer R, Cideciyan AV, de Juan E, Duncan JL, Eliott D, Fawzi A, Olmos de Koo LC, Brown GC, Haller JA, Regillo CD, Del Priore LV, Arditi A, Geruschat DR, Greenberg RJ; Argus II Study Group. Long-term results from an epiretinal prosthesis to restore sight to the blind. Ophthalmology. 2015;122:1547-1554.
34
Ozmert E, Demirel S. Endoscope-Assisted and Controlled Argus II Epiretinal Prosthesis Implantation in Late-Stage Retinitis Pigmentosa: A Report of 2 Cases. Case Rep Ophthalmol. 2016;7:315-324.
35
Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE, Cideciyan AV, Duncan JL, Eliott D, Filley E, Ho AC, Santos A, Safran AB, Arditi A, Del Priore LV, Greenberg RJ; Argus II Study Group. Interim Results from the International Trial of Second Sight’s Visual Prosthesis. Ophthalmology. 2012;119:779-788.
36
Geruschat DR, Richards TP, Arditi A, da Cruz L, Dagnelie G, Dorn JD, Duncan JL, Ho AC, Olmos de Koo LC, Sahel JA, Stanga PE, Thumann G, Wang V, Greenberg RJ. An analysis of observer-rated functional vision in patients implanted with the Argus II Retinal Prosthesis System at three years. Clin Exp Optom. 2016;99:227-232.
37
Ashwin Fale, Ajinkya Naik, Krishna Asegaonkar, Abhijeet Landge, Gaurav Atkare. Brainport Vision Technology. International Research Journal of Engineering and Technology (IRJET). 2016;3:475-483.
38
Lee VK, Nau AC, Laymon C, Chan KC, Rosario BL, Fisher C. Successful tactile based visual sensory substitution use functions independently of visual pathway integrity. Front Hum Neurosci. 2014;8:291
39
Öner A. Retina Hastalıklarında Kök Hücre Tedavisi: Son Gelişmeler. Turk J Ophthalmol. 2018;48:33-38.
40
Zarbin M. Cell-Based Therapy for Degenerative Retinal Disease. Trends Mol Med. 2016;22:115-134.
41
Oner A, Gonen ZB, Sinim N, Cetin M, Ozkul Y. Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa:a phase I clinical safety study. Stem Cell Res Ther. 2016;7:178.
42
Limoli PG, Limoli C, Vingolo EM, Scalinci SZ, Nebbioso M. Cell surgery and growth factors in dry age-related macular degeneration: visual prognosis and morphological study. Oncotarget. 2016;7:46913-46923.
43
Arslan U, Özmert E, Demirel S, Örnek F, Şermet F. Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results. Graefes Arch Clin Exp Ophthalmol. 2018;256:893-908.
44
Bittner AK, Seger K. Longevity of visual improvements following transcorneal electrical stimulation and efficacy of retreatment in three individuals with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2018;256:299-306.
45
Dias MF, Joo K, Kemp JA, Fialho SL, da Silva Cunha A Jr, Woo SJ, Kwon YJ. Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog Retin Eye Res. 2018;63:107-131.
46
Hohman TC. Hereditary Retinal Dystrophy. Handb Exp Pharmacol. 2017;242:337-367.
47
No Authors Listed. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy. Med Lett Drugs Ther. 2018;60:53-55.